TITLE

Window on financial developments

AUTHOR(S)
Desai, Suresh Thakur
PUB. DATE
February 2002
SOURCE
Chemical Business;Feb2002, Vol. 16 Issue 2, p41
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents updates on the chemical industry in India as of February 2002. Profits of Nerolac Paints for the quarter ended December 31, 2001; Net profit of Asian Paints for the quarter ended December 31, 2001; Loan of Nicholas Piramal group.
ACCESSION #
7142994

 

Related Articles

  • Nicholas Piramal sees a net rise 30%. Desai, Suresh Thakur // Chemical Business;Oct99, Vol. 13 Issue 10, p36 

    Deals with the profit expectation of Indian pharmaceutical company Nicholas Piramal Enterprises Limited in 1999-2000. Net profit of the company; Percentage growth in its pharmaceutical and glass businesses.

  • Nicholas Piramal to spin off. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the approval by shareholders of Nicholas Piramal of the spin-off of the glass and bulk drug units.

  • Nicholas Piramal net rises by 23%. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the financial performance of Nicholas Piramal India Ltd. in the fiscal period 1997-98.

  • Nerolac profits decline 7% on subdued demand.  // Chemical Business;Feb2013, Vol. 27 Issue 2, p59 

    The article reports on the decline in profits of Nerolac Paints Ltd. in the third quarter of financial year 2013.

  • NPI buys rights to Dobutrex brand. Tong, Alfred // Asian Chemical News;8/16/2004, Vol. 10 Issue 456, p8 

    Reports on the acquisition of rights to Eli Lilly's Dobutrex brand of cardiac stimulants by Nicholas Piramal India (NPI) in India. Generic name of the drug; Reasons behind the acquisition of Dobutrex; Sales of NPI for the year ended March 31, 2004.

  • Fine Chemical Firms Plan Multimillion-Dollar Investments. Scott, Alex // Chemical Week;2/28/2007, Vol. 169 Issue 7, p29 

    The article reports on the Informex fine and specialty chemicals expo held in San Francisco, California in February 2007. The event was awash with companies planning to install fine chemical manufacturing capacity. According to Cambrex it will spend $30 million-$60 million within the next three...

  • Innovations. O'Driscoll, Catherine // ICIS Chemical Business;6/26/2006, Vol. 1 Issue 25, p43 

    The article presents news briefs on the global chemical industry. Researchers at the University of Florence in Italy have discovered a new form of solid carbon dioxide that promises to be useful for making ultra-hard glass or coatings for microelectronic devices. Nicholas Piramal has announced...

  • The beginning of the end for EU specialities? Baker, John // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p5 

    This article reports on the effort of Asian producers to acquire assets in Europe as of October 2005. It was said that such efforts were made to gain market access and technology. According to reports, Avecia revealed it has struck a deal to sell its pharmaceutical custom synthesis business in...

  • NPH snags Avecia Pharmaceuticals.  // Chemical Market Reporter;10/31/2005, Vol. 268 Issue 15, p7 

    Reports on the acquisition of Great Britain-based custom synthesis and manufacturing firm Avecia Pharmaceuticals by Mumbai, India-based Nicholas Piramal India Ltd. Amount involved in the acquisition deal; Plan of Avecia to put the proceeds towards a deficit in the company's pension fund;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics